Federal Register / Vol. 69, No. 219 / Monday, November 15, 2004 / Notices 65611

heterologous to the recombinant virus. 

The antigenic sequences from pathogens 

such as influenza, RSV, measles, HPV, 

Epstein-Barr, Lassa, Polio, West Nile, 

Dengue, HIV–1 and 2, HTLV, herpes 

simplex virus, hepatitis viruses A, B, C, 

D, and E, Marburg, Ebola, and SARS are 

inserted into non-essential regions of 

either replication-competent or 

replication-defective adenovirus, adenoassociated virus (AAV), SV40 virus, 

herpes simplex virus, or vaccinia virus 

vectors that retain elements necessary 

for infectivity but are devoid of any 

pathogenic sequence elements. In these 

recombinant viruses, the antigenic 

sequences are operably linked to viral 

control elements. Thus, these 

recombinant viruses are capable of 

infecting a host and mounting an 

immune response specific to a given 

virus(es) without eliciting 

pathogenicity. In addition to the above, 

the technology also describes methods 

of accelerated pre-exposure or postexposure vaccination comprising singledose administration. The attractive 

features of this invention include the 

broad applicability of the recombinant 

viruses against a number of common 

pathogens and the potential of using 

them against other emergent infectious 

viruses; the ability of the vaccines to 

stimulate both cellular and humoral 

immune responses in humans and other 

hosts; and the ease of administration in 

single dose form via a number of routes. 

This technology is now available for 

licensing. Some fields of use may not be 

available.

Dated: November 9, 2004. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health.

[FR Doc. 04–25279 Filed 11–12–04; 8:45 am] 

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the meeting of the 

National Cancer Advisory Board. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

A portion of the meeting will be 

closed to the public in accordance with 

the provision set forth in section 

552b(6), as amended. The discussion 

could disclose personal information 

concerning NCI Staff and/or its 

contractors, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Cancer 

Advisory Board. 

Open: November 30, 2004, 8:30 a.m. to 

5:30 p.m. 

Agenda: Program reports and 

presentations; Business of the Board. 

Place: Name Cancer Institute, 9000 

Rockville Pike, Building 31, C Wing, 6th 

Floor, Conference Room 10, Bethesda, MD 

20892. 

Contact Person: Dr. Paulette S. Gray, 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, 8th Floor, Room 8001, 

Bethesda, MD 20892–8327, (301) 496–5147.

Name of Committee: National Cancer 

Advisory Board. 

Open: December 1, 2004, 8:30 a.m. to 10:30 

a.m. 

Agenda: Program reports and 

presentations; Business of the Board. 

Contact Person: Dr. Paulette S. Gray, 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, 8th Floor, Room 8001, 

Bethesda, MD 20892–8327, (301) 496–5147.

Name of Committee: National Cancer 

Advisory Board. 

Closed: December 1, 2004, 10:30 a.m. to 

adjournment. 

Agenda: Review intramural program site 

visit outcomes; Discussion of confidential 

personnel issues. 

Contact Person: Dr. Paulette S. Gray, 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, 8th Floor, Room 8001, 

Bethesda, MD 20892–8327, (301) 496–5147.

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

deainfo.nci.nih.gov/advisory/ncab.htm,

where an agenda and any additional 

information for the meeting will be posted 

when available.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS)

Dated: November 5, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–25271 Filed 11–12–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel, Urinary Infection. 

Date: December 7, 2004. 

Time: 8 a.m. to 5 p.m. 

Agenda: To reveiw and evaluate grant 

applications. 

Place: Courtyard By Marriott, 2899 

Jefferson Davis Highway, Arlington, VA 

22202. 

Contact Person: Maxine A. Lesniak, MPH, 

Scientific Review Administrator, Review 

Branch, DEA, NIDDK, National Institutes of 

Health, Room 756, 6707 Democracy 

Boulevard, Bethesda, MD 20892–5452, (301) 

594–7792, lesniakm@extra.niddk.nih.gov.

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel, Diabetes. 

Date: December 13, 2004. 

Time: 8 a.m. to 5 p.m. 

Agenda: To reveiw and evaluate grant 

applications. 

Place: Hyatt Regency—Crystal City, 2799 

Jefferson Davis Highway, Arlington, VA 

22202. 

Contact Person: Maxine A. Lesniak, MPH, 

Scientific Review Administrator, Review 

Branch, DEA, NIDDK, National Institutes of 

Health, Room 756, 6707 Democracy 

Boulevard, Bethesda, MD 20892–5452, (301) 

594–7792, lesniakm@extra.niddk.nih.gov.

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel, Clinical Studies of 

Kidney Disease. 

Date: December 16, 2004.

65612 Federal Register / Vol. 69, No. 219 / Monday, November 15, 2004 / Notices 

Time: 8 a.m. to 5 p.m. 

Agenda: To reveiw and evaluate grant 

applications. 

Place: Marriott Baltimore, Washington 

International Airport, 1743 West Nursery 

Road, Baltimore, MD 21240. 

Contact Person: Dan E. Matsumoto, PhD, 

Scientific Review Administrator, Review 

Branch, DEA, NIDDK, Room 749, 6707 

Democracy Boulevard, National Institutes of 

Health, Bethesda, MD 20892–5452, (301) 

594–8894, matsumotod@extra.niddk.nih.gov.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS)

Dated: November 4, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–25270 Filed 11–12–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Child Health and 

Human Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth is sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel, Communication of 

People with Mental Retardation. 

Date: December 6, 2004. 

Time: 9 a.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites at the Chevy Chase 

Pavilion, 4300 Military Road, NW., 

Washington, DC 20015. 

Contact Person: Marita R. Hopmann, PhD, 

Scientific Review Administrator, Division of 

Scientific Review, National Institute of Child 

Health and Human Development, 6100 

Building, Room 5B01, Bethesda, MD 20892, 

(301) 435–6911, hopmannm@mail.nih.gov.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS)

Dated: November 5, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–25272 Filed 11–12–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Child Health and 

Human Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel, Women’s 

Reproductive Health Research Career 

Development Program. 

Date: November 22, 2004. 

Time: 9:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Holiday Inn Select Bethesda, 8120 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Gopal M. Bhatnagar, PhD, 

Scientific Review Administrator, National 

Institute of Child Health and Human 

Development, National Institutes of Health, 

6100 Bldg Rm 5B01, Rockville, MD 20852, 

(301) 435–6889, bhatnagg@mail.nih.gov.

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS)

Dated: November 5, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–25273 Filed 11–12–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Child Health and 

Human Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel, Genes, Aneuploidy 

and Mamalian Development. 

Date: November 17, 2004. 

Time: 9:30 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Ramada Inn Rockville, 1775 

Rockville Pike, Rockville, MD 20852. 

Contact Person: Gopal M. Bhatnagar, PhD, 

Scientific Review Administrator, National 

Institutes of Child Health and Human 

Development, National Institutes of Health, 

6100 Bldg Rm 5B01, Rockville, MD 20852, 

(301) 435–6889, bhatnagg@mail.nih.gov.

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS)

Dated: November 5, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–25274 Filed 11–12–04; 8:45 am] 

BILLING CODE 4140–01–M